New Delhi: Drug firm Zydus Cadila on Wednesday said it has commenced supplies of its COVID-19 vaccine ZyCoV-D to the central government. The company has initiated the supply as per the order placed by the government, the drug firm said in a statement.The group is also planning to make the vaccine available in the private market, it added.ZyCoV-D is a three-dose vaccine...
New Delhi: Drug firm Zydus Cadila on Wednesday said it has commenced supplies of its COVID-19 vaccine ZyCoV-D to the central government. The company has initiated the supply as per the order placed by the government, the drug firm said in a statement.
The group is also planning to make the vaccine available in the private market, it added.
ZyCoV-D is a three-dose vaccine administered intradermally.
"The vaccine will be priced at Rs 265 per dose and the applicator being offered at Rs 93 per dose, excluding GST," Zydus Cadila said.
The Ahmedabad-based drugmaker has also entered into a definitive agreement with Shilpa Medicare Ltd, a contract manufacturing organisation, to produce mutually agreeable doses of ZyCoV-D.
It has also entered into an agreement with Enzychem Lifesciences of the Republic of Korea for the manufacturing license and technology transfer for the Plasmid DNA Vaccine, Zydus Cadila noted.
Zydus VTEC manufactures the drug substance for the needle-free DNA Plasmid vaccine, ZyCoV-D. The manufacturing process and in process material transfers within the plant are automated.
ZyCoV-D is a Plasmid DNA vaccine that produces the spike protein of the SARS-CoV-2 virus and elicits an immune response mediated by the cellular and humoral arms of the human immune system, which play a vital role in protection from disease as well as viral clearance.
The group is also planning to make the vaccine available in the private market. ZyCoV-D is a three dose vaccine administered intradermally using the painless PharmaJet® needle free system, Tropis®, on day 0, day 28 and day 56.
The Zydus group is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 23000 people worldwide and is dedicated to creating healthier communities globally.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd